JPRN-jRCT2080222775未知3 期
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Have a histopathologically confirmed diagnosis of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. All histologies of nonsquamous cell origin including undifferentiated gastric carcinoma are eligible.
- •-Have not received any prior first-line systemic therapy (prior adjuvant or neo-adjuvant therapy is permitted). Participants whose disease has progressed after >12 months following the last dose of systemic treatment in the adjuvant/neoadjuvant setting are eligible.
- •-Have measurable or nonmeasurable but evaluable disease determined using guidelines in Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1). Baseline tumor assessment should be performed using a high resolution computed tomography (CT) scan using IV and oral contrast unless clinically contra-indicated. Magnetic resonance imaging (MRI) is acceptable if a CT cannot be performed.
- •-Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale at baseline.
- •-Have adequate organ function.
- •-Have baseline clinical and laboratory parameters that are consistent with the requirements prescribed in respective labels and are suitable for consideration of treatment with capecitabine (or 5-FU) and cisplatin (for example, dihydropyrimidine dehydrogenase deficiency).
- •-Have an estimated life expectancy of >= 12 weeks in the judgment of the investigator.
排除标准
- •-Participants with adenocarcinoma of the esophagus are excluded.
- •-Participants with human epidermal growth factor receptor 2 (HER2)-positive status.
- •-Participants receiving chronic therapy with nonsteroidal anti-inflammatory agents.
- •-Have radiation therapy within 14 days prior to randomization.
- •-Have documented brain metastases, leptomeningeal disease or uncontrolled spinal cord compression.
- •-Have significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal tract within 12 weeks prior to randomization.
- •-Have experienced any arterial thromboembolic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to randomization.
- •-Have symptomatic congestive heart failure (New York Heart Association II-IV) or symptomatic or poorly controlled cardiac arrhythmia.
- •-Have uncontrolled hypertension prior to initiating study treatment, despite antihypertensive intervention.
- •-Have undergone major surgery within 28 days prior to randomization, or central venous access device placement within 7 days prior to first dose of study treatment, except if the procedure is minimally invasive (for example, introduction of peripherally inserted central catheter [PICC] line) and the investigator does not anticipate any significant bleeding.
- •-Have a history of gastrointestinal perforation and/or fistulae within 6 months prior to randomization.
- •-Have a history of inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) >= 12 months prior to randomization.
- •-Have an acute or subacute bowel obstruction or history of chronic diarrhea which is considered clinically significant in the opinion of the investigator.
- •-The participant has:
- •cirrhosis at a level of Child-Pugh B (or worse) or
- •cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis.
- •-Have known allergy or hypersensitivity to any components of study treatment.
- •-Are pregnant or lactating
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension - LVGYEUCTR2005-002692-33-DEilly ICOS LLC400
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients with Severe Traumatic Brain Injury - NDSevere brain injuryMedDRA version: 9.1Level: LLTClassification code 10060690EUCTR2010-018283-16-ITBHR PHARMA, LLC1,180
进行中（未招募）
1 期
A Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Patients with Active Ankylosing Spondylitis or Non-Radiographic Axial SpondyloarthritisAnkylosing spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)EUCTR2016-003936-19-HUSUN Pharmaceuticals Global FZE180
进行中（未招募）
不适用
The study is designed to determine the safety and efficacy of Progesterone in patients with severe head injurySevere traumatic brain injuryMedDRA version: 17.0Level: LLTClassification code 10060690Term: Traumatic brain injurySystem Organ Class: 100000004863EUCTR2010-018283-16-FIBHR Pharma, LLC1,180
进行中（未招募）
1 期
Study to evaluate the efficacy of IPI-145 administered in combination with rituximab vs placebo in combination with rituximab in subjects with previously treated CD20-positive FFollicular LymphomaEUCTR2013-002406-31-PLInfinity Pharmaceuticals, Inc400